This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Coghill, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Coghill, D.
Advances in Psychiatric Treatment (2003) 9: 289-299
© 2003 The Royal College of Psychiatrists

Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive–compulsive disorders, autism, Tourette’s and schizophrenia

Dave Coghill

Dave Coghill is senior lecturer in child and adolescent psychiatry in the Department of Psychiatry, University of Dundee (Ninewells Hospital and Medical School, Dundee DD1 9SR, UK. Tel.: 01382 204004; e-mail: david.coghill{at}tpct.scot.nhs.uk). He is also an honorary consultant child and adolescent psychiatrist in the Tayside Department of Child and Family Psychiatry. His main interests and research are in the neuropsychopharmacology of attention-deficit hyperactivity disorder and the psychopharmacology of child and adolescent psychiatric disorders. He is currently chair of the Royal College of Psychiatrists’ Faculty of Child and Adolescent Psychiatry Standing Group on Psychoactive Medication. He has received consultancy fees and travel costs by Janssen-Cilag and Eli Lilly.

This paper reviews the evidence base supporting the use of pharmacological treatments for child and adolescent psychiatric disorders. Recent advances in knowledge are highlighted, with some of the controversies. New evidence supports a role for selective serotonin reuptake inhibitors in the treatment of anxiety disorders and obsessive–compulsive disorder. Educational and behavioural approaches remain the mainstay of treatment for children and adolescents with autism, but there is evidence that adjunctive medication may be effective. Atypical antipsychotics have been investigated in the treatment of Tourette syndrome and early-onset schizophrenia. Many questions remain unanswered and further research is needed in all areas of paediatric psychopharmacology.




This article has been cited by other articles:


Home page
 PediatricsHome page
F. Rani, M. L. Murray, P. J. Byrne, and I. C. K. Wong
Epidemiologic Features of Antipsychotic Prescribing to Children and Adolescents in Primary Care in the United Kingdom
Pediatrics, May 1, 2008; 121(5): 1002 - 1009.
[Abstract] [Full Text] [PDF]